Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - piperonyl butoxide; pyrethrins; eucalyptus oil - shampoo - piperonyl butoxide benzodioxole active 10.0 g/l; pyrethrins pyrethroid-pyrethrin active 1.0 g/l; eucalyptus oil oil-plant extract other 10.0 g/l - parasiticides - cat | dog | dog - puppy | kitten | bitch | castrate | cat - queen | cat - tom | kitten | puppy | young cat - brown dog tick | flea - ctenocephalides spp. | dog tick

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - n-octyl bicycloheptene dicarboximide; piperonyl butoxide; pyrethrins - topical solution/suspension - n-octyl bicycloheptene dicarboximide bicyclo active 30.0 g/l; piperonyl butoxide benzodioxole active 18.0 g/l; pyrethrins pyrethroid-pyrethrin active 10.0 g/l - parasiticides - animal houses & living areas (domestic) | birds - ornamental | cat | dog | dog - puppy | kitten | amazon parrot | bird cage | bi - catbiting louse | dogbiting louse | flea - ctenocephalides spp. | louse | louse - heterodoxus spp. | paralysis tick | australian paralysis tick | cat louse | scrub tick

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - n-octyl bicycloheptene dicarboximide; piperonyl butoxide; pyrethrins - topical solution/suspension - n-octyl bicycloheptene dicarboximide bicyclo active 30.0 g/l; piperonyl butoxide benzodioxole active 18.0 g/l; pyrethrins pyrethroid-pyrethrin active 10.0 g/l - parasiticides - animal bedding | birds - ornamental | cat | dog | dog - puppy | kitten | rodent | amazon parrot | bitch | caged bird | canary | - brown dog tick | dogbiting louse | flea - ctenocephalides spp. | louse | louse - heterodoxus spp. | paralysis tick | tick | australian paralysis tick | dog tick | scrub tick

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 125ug;   - aerosol inhaler, metered dose - 125 mcg/dose - active: fluticasone propionate 125ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

Airija - anglų - HPRA (Health Products Regulatory Authority)

pco manufacturing - salmeterol xinafoate fluticasone propionate - pressurised inhalation suspension - 25/125 microgram

Kanada - anglų - Health Canada

the dial corporation - triclosan - liquid - .07% - triclosan .07% - disinfectants (for agents used on object)

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

meda pharmaceuticals inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 4 g in 60 ml - sfrowasa® (mesalamine) rectal suspension is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. sfrowasa® (mesalamine) rectal suspension is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, sulfites or any other component of this medication.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 10 mg - warfarin sodium tablets,usp are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets, usp have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. - pregnancy warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precau

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiell

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levaquin ® is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens , escherichia coli , klebsiella pneumoniae , haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levaquin ® is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus , streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae , haemophilus parainfluenzae , klebsiella pneumoniae , moraxella catarrhalis , chlamydophila pneumoniae , legionella pneumophila , or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] . mdrsp isolates ar